Logo image of LUNG

PULMONX CORP (LUNG) Stock Fundamental Analysis

NASDAQ:LUNG - Nasdaq - US7458481014 - Common Stock - Currency: USD

3.03  -0.11 (-3.5%)

After market: 3.03 0 (0%)

Fundamental Rating

3

LUNG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. LUNG may be in some trouble as it scores bad on both profitability and health. LUNG is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LUNG has reported negative net income.
In the past year LUNG has reported a negative cash flow from operations.
LUNG had negative earnings in each of the past 5 years.
In the past 5 years LUNG always reported negative operating cash flow.
LUNG Yearly Net Income VS EBIT VS OCF VS FCFLUNG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

LUNG's Return On Assets of -37.88% is on the low side compared to the rest of the industry. LUNG is outperformed by 62.77% of its industry peers.
LUNG's Return On Equity of -73.51% is in line compared to the rest of the industry. LUNG outperforms 41.49% of its industry peers.
Industry RankSector Rank
ROA -37.88%
ROE -73.51%
ROIC N/A
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
LUNG Yearly ROA, ROE, ROICLUNG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

LUNG has a better Gross Margin (73.47%) than 85.64% of its industry peers.
In the last couple of years the Gross Margin of LUNG has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for LUNG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
LUNG Yearly Profit, Operating, Gross MarginsLUNG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

LUNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LUNG has more shares outstanding
LUNG has more shares outstanding than it did 5 years ago.
LUNG has a worse debt/assets ratio than last year.
LUNG Yearly Shares OutstandingLUNG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
LUNG Yearly Total Debt VS Total AssetsLUNG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -3.30, we must say that LUNG is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.30, LUNG is not doing good in the industry: 68.09% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.38 indicates that LUNG is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.38, LUNG perfoms like the industry average, outperforming 45.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z -3.3
ROIC/WACCN/A
WACC9.03%
LUNG Yearly LT Debt VS Equity VS FCFLUNG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

LUNG has a Current Ratio of 4.97. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
LUNG's Current ratio of 4.97 is fine compared to the rest of the industry. LUNG outperforms 73.40% of its industry peers.
A Quick Ratio of 4.29 indicates that LUNG has no problem at all paying its short term obligations.
LUNG has a Quick ratio of 4.29. This is in the better half of the industry: LUNG outperforms 75.53% of its industry peers.
Industry RankSector Rank
Current Ratio 4.97
Quick Ratio 4.29
LUNG Yearly Current Assets VS Current LiabilitesLUNG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

LUNG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.09%, which is quite good.
The Revenue has grown by 19.84% in the past year. This is quite good.
The Revenue has been growing by 20.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)19.84%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%19.54%

3.2 Future

LUNG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.01% yearly.
Based on estimates for the next years, LUNG will show a very strong growth in Revenue. The Revenue will grow by 32.13% on average per year.
EPS Next Y-11.57%
EPS Next 2Y-1.49%
EPS Next 3Y4.38%
EPS Next 5Y29.01%
Revenue Next Year17.78%
Revenue Next 2Y17.98%
Revenue Next 3Y19.99%
Revenue Next 5Y32.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LUNG Yearly Revenue VS EstimatesLUNG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
LUNG Yearly EPS VS EstimatesLUNG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LUNG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LUNG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUNG Price Earnings VS Forward Price EarningsLUNG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUNG Per share dataLUNG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.49%
EPS Next 3Y4.38%

More info and screens

0

5. Dividend

5.1 Amount

LUNG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULMONX CORP

NASDAQ:LUNG (6/13/2025, 8:18:39 PM)

After market: 3.03 0 (0%)

3.03

-0.11 (-3.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners93.47%
Inst Owner Change1.63%
Ins Owners4.23%
Ins Owner Change13.06%
Market Cap121.99M
Analysts80
Price Target11.53 (280.53%)
Short Float %4.01%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.72%
Min EPS beat(2)11.73%
Max EPS beat(2)27.7%
EPS beat(4)4
Avg EPS beat(4)20.01%
Min EPS beat(4)11.73%
Max EPS beat(4)27.7%
EPS beat(8)8
Avg EPS beat(8)16.37%
EPS beat(12)12
Avg EPS beat(12)13.19%
EPS beat(16)15
Avg EPS beat(16)11.63%
Revenue beat(2)2
Avg Revenue beat(2)2.41%
Min Revenue beat(2)0.28%
Max Revenue beat(2)4.53%
Revenue beat(4)3
Avg Revenue beat(4)1.13%
Min Revenue beat(4)-1.48%
Max Revenue beat(4)4.53%
Revenue beat(8)7
Avg Revenue beat(8)2.91%
Revenue beat(12)9
Avg Revenue beat(12)2.12%
Revenue beat(16)11
Avg Revenue beat(16)2.9%
PT rev (1m)-2.88%
PT rev (3m)-3.08%
EPS NQ rev (1m)1.38%
EPS NQ rev (3m)-1.65%
EPS NY rev (1m)0.98%
EPS NY rev (3m)4.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.39
P/FCF N/A
P/OCF N/A
P/B 1.57
P/tB 1.62
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS2.17
BVpS1.93
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.88%
ROE -73.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.47%
FCFM N/A
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
F-Score2
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.22%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.97
Quick Ratio 4.29
Altman-Z -3.3
F-Score2
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)78.82%
Cap/Depr(5y)169.58%
Cap/Sales(3y)1.79%
Cap/Sales(5y)3.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-11.57%
EPS Next 2Y-1.49%
EPS Next 3Y4.38%
EPS Next 5Y29.01%
Revenue 1Y (TTM)19.84%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%19.54%
Revenue Next Year17.78%
Revenue Next 2Y17.98%
Revenue Next 3Y19.99%
Revenue Next 5Y32.13%
EBIT growth 1Y6.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.7%
EBIT Next 3Y17.14%
EBIT Next 5Y8.94%
FCF growth 1Y21.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.78%
OCF growth 3YN/A
OCF growth 5YN/A